Overview

* Liquidia ( LQDA ) reports Q2 product revenue of $6.5 mln following YUTREPIA launch

* Net loss for Q2 widens to $41.6 mln due to commercialization costs

* Co reports positive interim ASCENT trial data for YUTREPIA

Outlook

* Liquidia ( LQDA ) plans to expand market access for YUTREPIA in Q3 and Q4

* Company aims to scale YUTREPIA access and expand clinical programs

* Liquidia ( LQDA ) to present detailed clinical data at conferences in September and October

* Company targets occupancy of new manufacturing space in 2026

Result Drivers

* YUTREPIA LAUNCH - Over 900 unique patient prescriptions and 550 patient starts within 11 weeks post-approval, reflecting strong demand

* COMMERCIALIZATION COSTS - Increased expenses due to YUTREPIA launch and legal fees contributed to wider net loss

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $6.52

Revenue mln

Q2 Net -$41.58

Income mln

Q2 Basic -$0.49

EPS

Q2 -$37.50

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Liquidia Corp ( LQDA ) is $32.00, about 33.8% above its August 11 closing price of $21.20

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)